VANCOUVER, BRITISH COLUMBIA--(Marketwire - November 19, 2007) - Inflazyme Pharmaceuticals Ltd. (TSX: IZP) announced today that it has completed its previously announced sale of substantially all of its research and development assets to Biolipox AB. The transaction was approved at Inflazyme's AGM and Special Meeting of Shareholders on November 16, 2007. Of the votes cast, 98 per cent were in favor of the transaction.
